98%
921
2 minutes
20
This study aimed to establish whether a laboratory (lab) based 3-minute all-out (3MT) protocol and a field-based 3MT protocol would yield similar peak power (P), critical power (CP), and curvature constant (W') profiles and the implications of parameter estimation for informing a 40-km time trial (TT) performance. Nine competitive male cyclists (mean ± SD: age 36.5 ± 10.42 y, mass = 80.5 ± 10.6 kg, height 1.8 ± 0.1 m) completed two 3MTs on separate days, as well as a 40-km time trial. Both lab and field-based protocols evoked similar CP (p = 0.160) and W' (p = 0.200) profiles, but P (p = 0.012) may be more sensitive to biomechanical disparities and testing environment. Strong positive associations were observed with W'-kinetics (r = 0.73) and W' (r = 0.83) and moderate-to-strong negative associations with mean TT power (r = -0.75) and CP (r = -0.68). TT power outputs occur at 59-65% of CP, and finishing times appear to be informed by CP, W' and P with high degrees of accuracy (R2 > 0.90). Although TT performances occur predominantly within the moderate-to-heavy intensity domains, the mean intensity from a cardiovascular and core temperature perspective was high (i.e., ~90% HR; ~39°C). TT performances appear to be accurately informed by CP, W' and P, with W' dominating the predictive capacity associated with longer TT performances.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12408082 | PMC |
http://dx.doi.org/10.70252/NEFW5464 | DOI Listing |
Thromb Res
September 2025
Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. Electronic address:
Warfarin is a widely used vitamin K antagonist (VKA) with known pleiotropic effects beyond anticoagulation. Preclinical and case-control evidence suggests that warfarin may affect hematopoiesis, but longitudinal human evidence is lacking. To explore this potential effect, we conducted a post-hoc analysis of participants in the Hokusai-VTE and ENGAGE AF-TIMI 48 trials, which randomized patients to warfarin or the direct oral anticoagulant edoxaban with routine laboratory testing at predefined follow-up visits.
View Article and Find Full Text PDFInt J Orthop Trauma Nurs
August 2025
Autoimmune Diseases Research Center, Kashan University of Medical Sciences, Kashan, Iran. Electronic address:
Background: Knee osteoarthritis (KOA) is a prevalent degenerative joint disorder that significantly impairs physical function and daily activities. While conventional treatments focus on symptom management, complementary therapies such as aromatherapy massage have gained attention for their potential benefits.
Objective: This study evaluates the effects of peppermint oil aromatherapy massage on functional impairments in KOA patients.
J Med Internet Res
September 2025
Center for Healthy Minds and Department of Counseling Psychology, University of Wisconsin-Madison, Madison, WI, United States.
Background: Ecological momentary assessment (EMA) is increasingly being incorporated into intervention studies to acquire a more fine-grained and ecologically valid assessment of change. The added utility of including relatively burdensome EMA measures in a clinical trial hinges on several psychometric assumptions, including that these measure are (1) reliable, (2) related to but not redundant with conventional self-report measures (convergent and discriminant validity), (3) sensitive to intervention-related change, and (4) associated with a clinically relevant criterion of improvement (criterion validity) above conventional self-report measures (incremental validity).
Objective: This study aimed to evaluate the reliability, validity, and sensitivity to change of conventional self-report versus EMA measures of rumination improvement.
Ophthalmol Glaucoma
September 2025
Department of Ophthalmology and Visual Sciences, University of Michigan W.K. Kellogg Eye Center, Ann Arbor, Michigan. Electronic address:
Purpose: To investigate hand function and eye drop instillation success in adults with and without glaucoma.
Design: Cross-sectional pilot study.
Subjects: Adults aged ≥ 65 years with glaucoma who use eye drops daily and adults aged 65+ without glaucoma who do not regularly use eye drops.
J Infect Dis
September 2025
Biological Sciences, Sunnybrook Research Institute, Sunnybrook Hospital, Toronto, Ontario, Canada.
Background: Tecovirimat (TPOXX) is an antiviral authorized for the treatment of mpox infections in Canada, but recent clinical trials found it has no impact on symptom duration.
Methods: We conducted a prospective cohort study of individuals diagnosed with mpox in Toronto, Canada. Skin lesion swabs were collected weekly to quantify infectious monkeypox virus (MPXV) shedding through cell culture.